Alterola Biotech, Inc.
ABTI · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | 0.01 | -0.38 | -0.47 |
| FCF Yield | -1.72% | -0.82% | 0.33% | -1.97% |
| EV / EBITDA | -70.34 | -22.34 | 288.05 | -77.01 |
| Quality | ||||
| ROIC | 26.13% | -4.95% | -0.90% | -4.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.10 | -5.90 | 1.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -29.45% | -180.86% | 114.71% | -302.09% |
| Safety | ||||
| Net Debt / EBITDA | -12.52 | -2.32 | 11.07 | -2.37 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -92.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |